Vise Technologies Inc. Invests $307,000 in Hologic, Inc. (NASDAQ:HOLX)

Vise Technologies Inc. purchased a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 4,261 shares of the medical equipment provider's stock, valued at approximately $307,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Barclays PLC increased its position in shares of Hologic by 47.6% during the third quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider's stock worth $58,507,000 after purchasing an additional 231,578 shares in the last quarter. LaFleur & Godfrey LLC increased its position in Hologic by 2.9% in the 4th quarter. LaFleur & Godfrey LLC now owns 130,373 shares of the medical equipment provider's stock valued at $9,399,000 after acquiring an additional 3,655 shares during the period. Exchange Traded Concepts LLC increased its position in Hologic by 5.7% in the 4th quarter. Exchange Traded Concepts LLC now owns 20,764 shares of the medical equipment provider's stock valued at $1,497,000 after acquiring an additional 1,115 shares during the period. Blue Trust Inc. increased its position in Hologic by 18.4% in the 4th quarter. Blue Trust Inc. now owns 8,428 shares of the medical equipment provider's stock valued at $608,000 after acquiring an additional 1,310 shares during the period. Finally, KBC Group NV increased its position in Hologic by 6.6% in the 4th quarter. KBC Group NV now owns 93,376 shares of the medical equipment provider's stock valued at $6,731,000 after acquiring an additional 5,747 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Trading Down 1.3%

Shares of HOLX stock traded down $0.82 on Friday, reaching $62.10. 5,375,411 shares of the stock were exchanged, compared to its average volume of 2,268,610. The stock has a market cap of $13.84 billion, a P/E ratio of 19.59, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The firm has a 50 day moving average of $58.14 and a two-hundred day moving average of $65.80. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The business's revenue for the quarter was down 1.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.03 EPS. On average, research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Buying and Selling

In other news, Director Martin D. Madaus acquired 5,445 shares of the firm's stock in a transaction on Wednesday, May 7th. The stock was bought at an average cost of $55.24 per share, with a total value of $300,781.80. Following the transaction, the director now directly owns 5,445 shares in the company, valued at approximately $300,781.80. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.88% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

HOLX has been the topic of several recent research reports. Argus cut Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Leerink Partners lowered Hologic from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. Wall Street Zen lowered Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. William Blair restated an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Finally, Leerink Partnrs downgraded Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Twelve investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Hologic presently has an average rating of "Hold" and an average target price of $77.42.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.